Radiolabeled Study of CC-122 in Healthy Subjects

NCT02234999 | Completed Phase 1 DMC

• 1 other identifier: CC-122-CP-003
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the metabolism and excretion of \[14C\]-CC-122 in healthy male subjects

Conditions

Healthy Volunteers

Keywords

Pharmacokinetics, Healthy Subjects

Outcome Measures

Primary Outcomes (8)

• Total [14C]-radioactivity in biological matrices-Pharmacokinetics (PK)

  Biological matrices (whole blood, plasma, urine and feces) will be collected and analyzed for total \[14C\]-radioactivity

  Up to 12 days

• Cumulative excretion of total [14C]-radioactivity in urine and feces (PK)

  Urine and feces will be collected and analyzed for measurement of \[14C\]-radioactivity

  Up to 12 days

• Total [14C]-radioactivity whole blood-to-plasma ratios: PK

  Blood samples will be collected and analyzed for measurement of \[14C\]-radioactivity

  Up to 8 days

• Metabolite profiling/characterization in select biological matrices-PK

  Biological matrices (plasma, urine, and fecal samples) will be collected and select samples will undergo metabolite profiling/characterization

  Up to 12 dyas

• Peak (maximum) plasma concentration (Cmax) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate PK

  Blood samples will be collected and analyzed; Maximum observed plasma or whole blood concentration for up to 168 hours postdose will be calculated and reported as appropriate

  Up to 12 days

• Area under the plasma concentration-time curve (AUC) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate

  Blood samples will be collected and analyzed; Area under the concentration-time curve from time zero up to 168 hours postdose will be calculated and reported as appropriate

  Up to 12 days

• Time to maximum plasma concentration (Tmax) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate

  Blood samples will be collected and analyzed; Time to reach the observed maximum (peak) concentration will be calculated and reported as appropriate.

  Up to 12 days

• Terminal elimination half-life (t1/2) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate

  Blood samples will be collected and analyzed; Terminal half-life will be calculated and reported as appropriate

  Up to 12 days

Secondary Outcomes (1)

• The incidence, type, severity of adverse events (AE)

  Up to 28 days following dose; AEs will be collected and recorded from the time the subjects signs Informed Consent throughthe 28 day period following the of last dose of study drug

Study Arms (1)

3mg [14C]-CC-122 (Single Dose)

EXPERIMENTAL

Single oral capsule of 3mg \[14C\]-CC-122. given as a suspension under fasting conditions on Day 1

Drug: CC-122

Interventions

CC-122 DRUG

3mg \[14C\]-CC-122 will be administered as a single dose

3mg [14C]-CC-122 (Single Dose)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• \. Healthy adult male of any race and between 18 years of age to 55 years of age, inclusive, at the time of signing the informed consent document.
• \. Understand and voluntarily sign an informed consent document before any study related assessments/procedures are performed.
• \. Able to adhere to the study visit schedule and other protocol requirements. 4. Must practice true abstinence or agree to use a condom (a latex condom is recommended) during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and for at least 28 days following discontinuation of investigational product, even if he has undergone a successful vasectomy.
• \. Must agree to abide by the CC 122 Pregnancy Prevention Risk Management Plan 6. Must have a body mass index between 18 and 33 kg/m2, inclusive, at screening.
• \. Must be healthy as determined by the Investigator on the basis of medical history, physical exam, clinical laboratory test results, vital signs, and 12-lead electrocardiogram at screening:
• Must be afebrile (febrile is defined as ≥ 38.5°C or 101.3°F)
• Supine systolic blood pressure must be in the range of 90 to 140 mmHg, supine diastolic blood pressure must be in the range of 50 to 90 mmHg, and pulse rate must be in the range of 40 to 110 bpm
• Normal or clinically acceptable 12 lead electrocardiogram, with a QTcF value ≤ 430 msec

You may not qualify if:

• \. History of any clinically significant and relevant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies (including a known hypersensitivity to a member of the class of IMiDs®), or other major disorders.
• \. Any condition, including the presence of clinically significant laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study.
• \. Any condition that confounds the ability to interpret data from the study. 4. Exposed to an investigational drug (new chemical entity) within 30 days preceding dose administration, or five half lives of that investigational drug, if known (whichever is longer).
• \. Participation in more than one other radiolabeled investigational drug study within 12 months prior to check in.
• Note: The previous radiolabeled investigational drug must have been received more than 6 months prior to check in and the total planned exposure from this current study and the previous study must be within the recommended levels considered safe, per United States Code of Federal Regulations governing Protection of Human Subjects; radioactive drugs for certain research uses.
• \. Exposure to significant radiation (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to check in.
• \. Used any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 30 days of dose administration.
• \. Used any nonprescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of dose administration.
• \. Used cytochrome P450 3A inducers and/or inhibitors (including St. John's wort) within 30 days of dose administration.
• \. Donated blood or plasma within 8 weeks before dose administration to a blood bank or blood donation center.
• \. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual) within 2 years before dose administration, or positive drug screening test reflecting consumption of illicit drugs.
• \. History of alcohol abuse (as defined by the current version of the Diagnostic and Statistical Manual) within 2 years before dose administration, or positive alcohol screen.
• \. Known to have serum hepatitis or known to be a carrier of hepatitis B surface antigen or hepatitis C antibodies, or have a positive result to the test for HIV antibodies at screening.
• \. Smokes more than 10 cigarettes per day, or the equivalent in other tobacco products (self reported).
• \. Part of the clinical site staff personnel or family members of the clinical site staff.

Sponsors & Collaborators

• Celgene: lead

Study Sites (1)

Covance Clinical Research Unit Inc

Madison, Wisconsin, 53704, United States

Location

MeSH Terms

Interventions

3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione

Study Officials

• Edward O'Mara, MD

  Celgene Corporation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 5, 2014
• First Posted: September 9, 2014
• Study Start: September 23, 2014
• Primary Completion: October 8, 2014
• Study Completion: October 8, 2014
• Last Updated: November 12, 2019

Record last verified: 2019-11

Locations

US (1)